;PMID: 9797083
;source_file_1392.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:38..133] = [t:38..133]
;2)section:[e:137..220] = [t:137..220]
;3)section:[e:224..343] = [t:224..343]
;4)sentence:[e:347..513] = [t:347..513]
;5)sentence:[e:514..709] = [t:514..709]
;6)sentence:[e:710..989] = [t:710..989]
;7)sentence:[e:990..1072] = [t:990..1072]
;8)sentence:[e:1073..1177] = [t:1073..1177]
;9)section:[e:1181..1225] = [t:1181..1225]

;section 0 Span:0..33
;Ann Hematol  1998 Sep;77(3):131-4
(SEC
  (FRAG (DT:[0..3] Ann) (NNP:[4..11] Hematol) (CD:[13..17] 1998)
        (CD:[18..25] Sep;77-LRB-) (CD:[25..26] 3) (-RRB-:[26..27] -RRB-)
        (CD:[27..31] :131) (HYPH:[31..32] -) (CD:[32..33] 4)))

;sentence 1 Span:38..133
;c-kit mutation and osteopetrosis-like osteopathy in a patient with systemic
;mast  cell disease.
;[38..43]:gene-rna:"c-kit"
;[105..132]:malignancy:"systemic mast  cell disease"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[38..43] c-kit) (NN:[44..52] mutation))
      (CC:[53..56] and)
      (NP
        (ADJP (NN:[57..70] osteopetrosis) (HYPH:[70..71] -) (JJ:[71..75] like))
        (NN:[76..86] osteopathy)))
    (PP-LOC (IN:[87..89] in)
      (NP
        (NP (DT:[90..91] a) (NN:[92..99] patient))
        (PP (IN:[100..104] with)
          (NP (JJ:[105..113] systemic)
            (NML (NN:[114..118] mast) (NN:[120..124] cell))
            (NN:[125..132] disease)))))
    (.:[132..133] .)))

;section 2 Span:137..220
;Reinacher-Schick A, Petrasch S, Longley BJ, Teschendorf C, Graeven U,
;Schmiegel  W.
(SEC
  (FRAG (NNP:[137..146] Reinacher) (HYPH:[146..147] -) (NNP:[147..153] Schick)
        (NNP:[154..155] A) (,:[155..156] ,) (NNP:[157..165] Petrasch)
        (NNP:[166..168] S,) (NNP:[169..176] Longley) (NNP:[177..179] BJ)
        (,:[179..180] ,) (NNP:[181..192] Teschendorf) (NNP:[193..194] C)
        (,:[194..195] ,) (NNP:[196..203] Graeven) (NNP:[204..205] U)
        (,:[205..206] ,) (NNP:[207..216] Schmiegel) (NNP:[218..220] W.)))

;section 3 Span:224..343
;Department of Medicine, Knappschaftskrankenhaus, Ruhr University, Bochum, 
;Germany. Anke.C.Reinacher@ruhr-uni-bochum.de
(SEC
  (FRAG (NNP:[224..234] Department) (IN:[235..237] of) (NNP:[238..246] Medicine)
        (,:[246..247] ,) (NNP:[248..271] Knappschaftskrankenhaus)
        (,:[271..272] ,) (NNP:[273..277] Ruhr) (NNP:[278..288] University)
        (,:[288..289] ,) (NNP:[290..296] Bochum) (,:[296..297] ,)
        (NNP:[299..306] Germany) (.:[306..307] .) (NNP:[308..312] Anke)
        (NNP:[312..315] .C.) (NNP:[315..329] Reinacher@ruhr) (HYPH:[329..330] -)
        (JJ:[330..333] uni) (HYPH:[333..334] -) (JJ:[334..340] bochum)
        (NN:[340..343] .de)))

;sentence 4 Span:347..513
;We describe the case of a 69-year-old man with systemic mastocytosis and
;severe  osteopetrosis who carries a somatic activating mutation in the c-kit 
;proto-oncogene.
;[394..415]:malignancy:"systemic mastocytosis"
;[491..496]:gene-rna:"c-kit"
(SENT
  (S
    (NP-SBJ (PRP:[347..349] We))
    (VP (VBP:[350..358] describe)
      (NP
        (NP (DT:[359..362] the) (NN:[363..367] case))
        (PP (IN:[368..370] of)
          (NP
            (NP
              (NP (DT:[371..372] a)
                (ADJP
                  (NML (CD:[373..375] 69) (HYPH:[375..376] -)
                       (NN:[376..380] year))
                  (HYPH:[380..381] -) (JJ:[381..384] old))
                (NN:[385..388] man))
              (PP (IN:[389..393] with)
                (NP
                  (NP (JJ:[394..402] systemic) (NN:[403..415] mastocytosis))
                  (CC:[416..419] and)
                  (NP (JJ:[420..426] severe) (NN:[428..441] osteopetrosis)))))
            (SBAR
              (WHNP-1 (WP:[442..445] who))
              (S
                (NP-SBJ-1 (-NONE-:[445..445] *T*))
                (VP (VBZ:[446..453] carries)
                  (NP (DT:[454..455] a) (JJ:[456..463] somatic)
                      (VBG:[464..474] activating) (NN:[475..483] mutation))
                  (PP-LOC (IN:[484..486] in)
                    (NP (DT:[487..490] the) (NN:[491..496] c-kit)
                        (AFX:[498..503] proto) (HYPH:[503..504] -)
                        (NN:[504..512] oncogene))))))))))
    (.:[512..513] .)))

;sentence 5 Span:514..709
;The patient initially presented with urticaria pigmentosa,  progressing to
;systemic mast cell disease with severe anemia due to bone marrow 
;involvement, chronic diarrhea, and hepatosplenomegaly.
;[551..571]:malignancy:"urticaria pigmentosa"
;[589..615]:malignancy:"systemic mast cell disease"
(SENT
  (S
    (NP-SBJ (DT:[514..517] The) (NN:[518..525] patient))
    (ADVP-TMP (RB:[526..535] initially))
    (VP (VBD:[536..545] presented)
      (PP (IN:[546..550] with)
        (NP (NN:[551..560] urticaria) (NN:[561..571] pigmentosa)))
      (,:[571..572] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[572..572] *))
        (VP (VBG:[574..585] progressing)
          (PP (TO:[586..588] to)
            (NP
              (NP (JJ:[589..597] systemic)
                (NML (NN:[598..602] mast) (NN:[603..607] cell))
                (NN:[608..615] disease))
              (PP (IN:[616..620] with)
                (NP (JJ:[621..627] severe) (NN:[628..634] anemia)))))
          (PP (JJ:[635..638] due)
            (PP (TO:[639..641] to)
              (NP
                (NP
                  (NML (NN:[642..646] bone) (NN:[647..653] marrow))
                  (NN:[655..666] involvement))
                (,:[666..667] ,)
                (NP (JJ:[668..675] chronic) (NN:[676..684] diarrhea))
                (,:[684..685] ,) (CC:[686..689] and)
                (NP (NN:[690..708] hepatosplenomegaly))))))))
    (.:[708..709] .)))

;sentence 6 Span:710..989
;Direct sequencing using  amplimers from reverse transcriptase-polymerase
;chain reactions (RT-PCR) from  skin mast cell-derived RNA revealed a point
;mutation in the c-kit proto-oncogene  at position 2468, introducing a new
;recognition site for the restriction  endonuclease HinfI.
;[750..771]:gene-protein:"reverse transcriptase"
;[772..782]:gene-protein:"polymerase"
;[852..866]:variation-type:"point mutation"
;[874..879]:gene-rna:"c-kit"
;[899..912]:variation-location:"position 2468"
;[983..988]:gene-protein:"HinfI"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[710..716] Direct) (NN:[717..727] sequencing))
      (VP (VBG:[728..733] using)
        (NP
          (NP (NNS:[735..744] amplimers))
          (PP (IN:[745..749] from)
            (NP
              (NP
                (NML (JJ:[750..757] reverse) (NN:[758..771] transcriptase))
                (HYPH:[771..772] -)
                (NML (NN:[772..782] polymerase) (NN:[783..788] chain)
                     (NNS:[789..798] reactions)))
              (NP (-LRB-:[799..800] -LRB-)
                (NML (NN:[800..802] RT))
                (HYPH:[802..803] -)
                (NML (NN:[803..806] PCR))
                (-RRB-:[806..807] -RRB-))))
          (PP (IN:[808..812] from)
            (NP (NN:[814..818] skin)
              (ADJP
                (NML (NN:[819..823] mast) (NN:[824..828] cell))
                (HYPH:[828..829] -) (VBN:[829..836] derived))
              (NN:[837..840] RNA))))))
    (VP (VBD:[841..849] revealed)
      (NP
        (NP
          (NP (DT:[850..851] a)
             (NN:[852..857] point) (NN:[858..866] mutation))
          (PP-LOC (IN:[867..869] in)
            (NP (DT:[870..873] the) (NN:[874..879] c-kit) (AFX:[880..885] proto)
                (HYPH:[885..886] -) (NN:[886..894] oncogene)))
          (PP-LOC (IN:[896..898] at)
            (NP (NN:[899..907] position) (CD:[908..912] 2468))))
        (,:[912..913] ,)
        (VP (VBG:[914..925] introducing)
          (NP (DT:[926..927] a) (JJ:[928..931] new) (NN:[932..943] recognition)
              (NN:[944..948] site))
          (PP (IN:[949..952] for)
            (NP
              (NP (DT:[953..956] the) (NN:[957..968] restriction)
                  (NN:[970..982] endonuclease))
              (NP (NN:[983..988] HinfI)))))))
    (.:[988..989] .)))

;sentence 7 Span:990..1072
;Treatment with interferon-alpha 2a, prednisone, and  erythropoietin was
;initiated.
;[1005..1024]:gene-protein:"interferon-alpha 2a"
;[1043..1057]:gene-protein:"erythropoietin"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[990..999] Treatment))
      (PP (IN:[1000..1004] with)
        (NP
          (NP (NN:[1005..1021] interferon-alpha) (NN:[1022..1024] 2a))
          (,:[1024..1025] ,)
          (NP (NN:[1026..1036] prednisone))
          (,:[1036..1037] ,) (CC:[1038..1041] and)
          (NP (NN:[1043..1057] erythropoietin)))))
    (VP (VBD:[1058..1061] was)
      (VP (VBN:[1062..1071] initiated)
        (NP-1 (-NONE-:[1071..1071] *))))
    (.:[1071..1072] .)))

;sentence 8 Span:1073..1177
;Subsequently, clinical symptoms improved  significantly and hemoglobin levels
;are now stable at 13 g/dl.
;[1133..1143]:gene-protein:"hemoglobin"
(SENT
  (S
    (S
      (ADVP-TMP (RB:[1073..1085] Subsequently))
      (,:[1085..1086] ,)
      (NP-SBJ (JJ:[1087..1095] clinical) (NNS:[1096..1104] symptoms))
      (VP (VBD:[1105..1113] improved)
        (ADVP (RB:[1115..1128] significantly))))
    (CC:[1129..1132] and)
    (S
      (NP-SBJ (NN:[1133..1143] hemoglobin) (NNS:[1144..1150] levels))
      (VP (VBP:[1151..1154] are)
        (ADVP-TMP (RB:[1155..1158] now))
        (ADJP-PRD (JJ:[1159..1165] stable))
        (PP (IN:[1166..1168] at)
          (NP
            (NP (CD:[1169..1171] 13) (NN:[1172..1173] g))
            (PP (SYM:[1173..1174] /)
              (NP (NN:[1174..1176] dl)))))))
    (.:[1176..1177] .)))

;section 9 Span:1181..1225
;PMID: 9797083 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1181..1185] PMID) (::[1185..1186] :) (CD:[1187..1194] 9797083)
        (IN:[1195..1196] -LSB-) (NNP:[1196..1202] PubMed) (HYPH:[1203..1204] -)
        (JJ:[1205..1212] indexed) (IN:[1213..1216] for)
        (NNP:[1217..1225] MEDLINE-RSB-)))
